Literature summary for 1.17.4.1 extracted from

Karp, J.E.; Giles, F.J.; Gojo, I.; Morris, L.; Greer, J.; Johnson, B.; Thein, M.; Sznol, M.; Low, J.
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloprol (2008), Leuk. Res., 32, 71-77.

Search for more literature for 1.17.4.1

Inhibitors

Inhibitors	Comment	Organism	Structure
3-aminopyridine-2-carboxaldehyde thiosemicarbazone	i.e.3-AP or triapine, in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloprol, phase I study, detailed overview, the inhibitor inhibits the M2 subunit, and depletes intracellular deoxyribonculeotide pools, especially dATP	Homo sapiens
Hydroxyurea	inhibits the M2 subunit	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	adults with refractory acute leukemias and aggressive myeloproliferative disorders, MPD	-

Subunits

Subunits	Comment	Organism
tetramer	2 * M1-subunit + 2 * M2-subunit	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)